Literature DB >> 10967217

Current status of DNA vaccines in veterinary medicine.

B R Krishnan1.   

Abstract

DNA vaccination entails administration of the DNA itself encoding antigen to direct synthesis of the antigen directly in the target organism. The target organism's immune system recognizes the antigen, and generates humoral (antibody)- and/or cell-mediated immune response. DNA vaccines afford numerous advantages over conventional vaccines, including ease of production, stability and transport. They overcome the need to cultivate dangerous infectious agents, and provide a possibility to vaccinate against multiple pathogens in a single shot. DNA vaccination is beginning to be explored for many pathogens of veterinary interest. The status of DNA vaccines in poultry, livestock and companion animals is reviewed here. While examples of DNA vaccines being tested in the veterinary field are not numerous, the early studies highlight the potential DNA vaccinology offers in veterinary medicine.

Mesh:

Substances:

Year:  2000        PMID: 10967217     DOI: 10.1016/s0169-409x(00)00073-9

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  4 in total

1.  Induction of immune response in BALB/c mice with a DNA vaccine encoding bacterioferritin or P39 of Brucella spp.

Authors:  A Al-Mariri; A Tibor; P Mertens; X De Bolle; P Michel; J Godfroid; K Walravens; J J Letesson
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

2.  Yersinia enterocolitica as a vehicle for a naked DNA vaccine encoding Brucella abortus bacterioferritin or P39 antigen.

Authors:  Ayman Al-Mariri; Anne Tibor; Pascal Lestrate; Pascal Mertens; Xavier De Bolle; Jean-Jacques Letesson
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

3.  Evolving importance of biologics and novel delivery systems in the face of microbial resistance.

Authors:  Terry L Bowersock
Journal:  AAPS PharmSci       Date:  2002

Review 4.  DNA vaccines in veterinary use.

Authors:  Laurel Redding; David B Weiner
Journal:  Expert Rev Vaccines       Date:  2009-09       Impact factor: 5.217

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.